Posted in | News

Bayer Develops Explosion Resistant Solution for Buildings

Bayer MaterialScience, a producer of high-performance plastics and high-tech polymers, has developed an advanced solution for protecting buildings and occupants from explosive attacks.

The Bayer MaterialScience LLC Hygard® BL80 Shock-Wave Sentinel’s blast-resistant structural envelope offers a new level of protection for buildings and occupants and avoids re-construction or moving costs associated with traditional solutions.

The Hygard BL80 Shock-Wave Sentinel is a blast-resistant structural envelope that preserves the aesthetic appearance of buildings. It can be incorporated into the structure of the buildings.

Bayer’s Hygard BL80 overcomes the disadvantages associated with traditional approaches. It is designed to protect the building structure. It minimizes damage by absorbing the shock wave of bomb blasts. The Hygard BL80 can withstand explosive blasts that generate an impulse of 380 psi-msec and a pressure of 80 psi. These values are 30% higher than the tough explosion resistance standards. The blast-resistant structural envelope demonstrated these properties in the open-range and shock-tube testing.

The Hygard BL80 Shock-Wave Sentinel preserves the functionality of the building. It adds to the architectural aesthetics of the building. The product can be used in new structures and can also be used for retrofitting of the existing structures. During construction, the necessity for temporary relocation can be avoided. It will also minimize the disruption of operations that occur due to location.

The Hygard BL80 product can protect the structural integrity of the building and the occupants of the building as well. Bayer will be manufacturing the patent-pending Hygard BL80 in compliance with procedures and processes compliant with ISO-9001.

The marketing leader for the Public Sector Business at Bayer MaterialScience, Roger Rumer, has said that the Hygard BL80 would contribute to the security of critical buildings, infrastructure and their occupants.

Source: http://www.bayermaterialscience.com/

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 22). Bayer Develops Explosion Resistant Solution for Buildings. AZoBuild. Retrieved on November 24, 2024 from https://www.azobuild.com/news.aspx?newsID=14360.

  • MLA

    Scanlon, Joel. "Bayer Develops Explosion Resistant Solution for Buildings". AZoBuild. 24 November 2024. <https://www.azobuild.com/news.aspx?newsID=14360>.

  • Chicago

    Scanlon, Joel. "Bayer Develops Explosion Resistant Solution for Buildings". AZoBuild. https://www.azobuild.com/news.aspx?newsID=14360. (accessed November 24, 2024).

  • Harvard

    Scanlon, Joel. 2019. Bayer Develops Explosion Resistant Solution for Buildings. AZoBuild, viewed 24 November 2024, https://www.azobuild.com/news.aspx?newsID=14360.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.